The introduction of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML) by selectively targeting the BCR-ABL protein, thereby obstructing its oncogenic function and addressing the unchecked cell growth characteristic of this leukemia [82,83]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.